Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 2/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27526991 | 0.99 | BCHE (0.56) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL10848318 | 0.96 | ALOX5 (0.51) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL5407867 | 0.93 | BCHE (0.55) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL19533628 | 0.91 | BCHE (0.53) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL29151455 | 0.91 | ALOX5 (0.47) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL6659347 | 0.89 | ALOX5 (0.59) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL4321470 | 0.86 | SMN1; SMN2 (0.51) | BCHEACHELTA4HALDH1A1MAPK1 | |
| SCHEMBL20506778 | 0.86 | ALDH1A1 (0.49) | BCHEACHELTA4HALDH1A1ALOX5 | |
| SCHEMBL3184733 | 0.86 | ALDH1A1 (0.54) | LTA4HALDH1A1ALOX5SMN1; SMN2LMNA | |
| SCHEMBL31301745 | 0.86 | ALOX5 (0.52) | BCHEACHEHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112538084-B | Novel KRAS G12C protein inhibitor and preparation method and application thereof | 信达生物制药(苏州)有限公司 | 2023-06-20 | — | — | CN | disclosed |
| EP-3246317-B1 | BTK INHIBITOR | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-112538084-A | Novel KRAS G12C protein inhibitor and preparation method and application thereof | 信达生物制药(苏州)有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| CN-100355758-C | Guanidine derivatives and use thereof as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2007-12-19 | — | — | CN | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
| CN-1761673-A | guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-19 | — | — | CN | disclosed |
| EP-1608662-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083218-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | BCHE 1147/4885ACHE 516/4885HDAC3 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.